
|Articles|December 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 12
- Volume 16
- Issue 12
Encouraging Avastin results in glioblastoma multiforme
Encouraging Avastin results in glioblastoma multiforme
Advertisement
DALLASPhase II data showed 6-month progression-free survival in 36% of relapsed glioblastoma patients given Avastin (bevacizumab) alone and 51% given Avastin plus irinotecan (Camptosar), compared with historical estimates of 15%. UCLA's Timothy Cloughesy, MD, reported the findings at the Society for Neuro-Oncology annual meeting.
Articles in this issue
over 18 years ago
Third-line single-agent cetuximab ups overall survivalover 18 years ago
Modern multislice CT propels pancreas imaging forwardover 18 years ago
Sorafenib gets ok for liver cancerover 18 years ago
Celgene to acquire Pharmionover 18 years ago
Novacea halts ASCENT-2 trialover 18 years ago
RT/temozolomide raises possibility of cure in glioblastomaover 18 years ago
Brachytherapy as effective in younger as in older menover 18 years ago
MMA not harming patientsover 18 years ago
Kinase inhibitor may prevent RT-induced lung injuryover 18 years ago
FDA approves lower starting dose for dasatinib for CMLNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Sunvozertinib Improves PFS vs Chemotherapy in EGFR+ NSCLC
2
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
3
The Evolution of Artificial Intelligence in Oncology: Impact on Trials, Workflows, and Outcomes
4
Considering Venlafaxine as Distress Treatment in Breast Cancer
5





















































